Skip to content
Updates in relapsed/refractory Multiple Myeloma
Chronic Lymphocytic Leukemia
T-Cell NHL- Novel therapies
B-Cell NHL (Aggressive)-Relapsed (CAR T versus Bispecifics?)
Lung Cancer Screening Programs: How do We ‘Take it to the Next Level’ to Improve Lung Cancer Outcomes?
Existing and Emerging Tests for Cancer Interception: How Low do We have to Go (with the LOD)? Does Methylation Help?
Incidental Pulmonary Nodule Programs (IPNs) – What are Best Practices for Monitoring and Diagnosing?
Assessing the Cancer Risk of Lung Nodules by Proteomic or Gene Expression Platforms
What is the Best Way to Assess Response to Therapy? Is Complete Pathologic Response the Best Surrogate?
Perioperative Chemo/Immunotherapy and Surgical Outcomes
Debate- Is Perioperative Immunotherapy the New Standard of Care? Yes.
Debate- Is Perioperative Immunotherapy the New Standard of Care? No.
Which Patients Need Adjuvant Therapy?
Update Progress in Targeted Therapies for Early-Stage NSCLC
Assessing Resectability in Stage III NSCLC
Combining Immunotherapy with Radiation for LA-NSCLC
Moving the Bar Beyond PACIFIC. What is the Best Consolidation Therapy for People with Actionable and Non-Actionable Genes?
Progress in Biomarkers for SCLC – Are We Ready for Implementation into Routine Clinical Practice?
Treatment for SCLC in 2024: Where Are We At?
The Future of SCLC Treatment: Potential Agents and Where Are We Going?
Role of Radiation Therapy in SCLC
The Era of Antibody-Drug Conjugates (ADCs) and Bi-Specifics
Resistance to KRAS Inhibitors
Post navigation
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Ok 
